Journal
MOVEMENT DISORDERS
Volume 24, Issue 1, Pages 126-129Publisher
WILEY
DOI: 10.1002/mds.22376
Keywords
Huntington's disease; aripiprazole; tetrabenazine; neuroleptics
Categories
Funding
- Italian Ministry of Health [EBRI1.O, PS05.11, PS05.21, REG.13M, RF06.70M]
- Comitato Telethon Fondazione Onlus
- Amministrazione Autonoma dei Monopoli di Stato (AAMS)
- Italian city of Gubbio [GGP06209]
Ask authors/readers for more resources
Aripiprazole (AP), a dopamine (DA) D-2 receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington's disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare the effects of AP vs. TBZ in a small study of six patients with HD. Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way. However, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial. Moreover, AP showed a slight but not significant improvement of depression in the patients as compared to TBZ. A larger group of patients and a longer period of observation are an important prerequisite for further evaluations of AP's therapeutic use. (c) 2008 Movement Disorder Society
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available